The Claim
In Pkd1RC/RC mice, a model of autosomal dominant polycystic kidney disease, treatment with fenofibrate, a PPARα agonist, is associated with increased expression of PPARα and genes involved in fatty acid β-oxidation and oxidative phosphorylation, along with higher rates of β-oxidation in kidney tissue, suggesting enhanced mitochondrial metabolism in this animal model.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with a kidney disease similar to one in humans, giving them a drug called fenofibrate seems to boost the activity of genes that help burn fat for energy in the kidneys, which might mean their kidney cells are using energy more efficiently.
See the scientific wording
In Pkd1RC/RC mice, a model of autosomal dominant polycystic kidney disease, treatment with fenofibrate, a PPARα agonist, is associated with increased expression of PPARα and genes involved in fatty acid β-oxidation and oxidative phosphorylation, along with higher rates of β-oxidation in kidney tissue, suggesting enhanced mitochondrial metabolism in this animal model.
What the research says
1 studyThe study gave fenofibrate to kidney disease mice and found it boosted fat-burning and energy production in their kidneys, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.